Clinical trials, by their very nature, are a kind of second choice involving uncertainty from the beginning. The inherent characteristics of clinical trials necessitate ethical considerations. Ethical analysis emphasizes the importance of medical indications, patient preferences, trial quality, and contextual features. Instances of clinical trial misconduct are usually due to insufficient analysis of medical indications, which ignore patient preferences and the way in which investigators assess clinical trial results. These problems are universal concerns. In the context of clinical trials, these are subjective needs in every society. For clinical trials conducted in Asia, ethics must consider the specific needs and benefits of Asian people.
INTRODUCTION
UNCERTAINTY IS THE primary reason to conduct clinical trials. Uncertainty means that certain issues surrounding clinical trials are unresolved, and must be analyzed scientifically, morally, and ethically. Medical morals dictate the actions and beliefs that regulate the day-to-day judgments of doctors, and medical ethics analyzes the universal principles on which decisions are made (1) . Engelhardt suggests that ethical or bioethical evaluation is required whenever unfamiliar moral issues are encountered (2) .
Thus, ethical analysis is important in clinical trials that are now conducted internationally in countries with different values and morals. In dealing with such ethical issues, Jonsen's four-element structure analysis is a 
ANALYSIS OF CLINICAL ETHICS

Medical Indications (Beneficence or Nonmaleficence)
Medical interventions form the gateway for further diagnostic, therapeutic, and preventive activities. Issues at this stage may include medical goals, efficacy, risk, necessity, and overall goals. The patient needs to be cured or cared for. In preventive trials, the intervention must prevent healthy persons from becoming ill. Clinical trials are proposed because the need for medical intervention is obvious.
Medical indications are primarily technical, hence this element is not a serious concern in clinical trials. However, medical indi-cations may become a subject of discussion if any uncertainty remains in the set up of clinical trials. For example, if the use of a surrogate endpoint is inevitable in the trial, there will definitely be uncertainty in the medical indications for that clinical trial. In an extreme situation, some medical goals are unrealistic today but they may become realistic tomorrow. Thus, it is crucial to assess medical goals thoroughly before proceeding to trials.
Reviewing existing data on the test substance is an essential part of clinical trials, particularly to prevent adverse events and avoid risks. This has often been neglected or oversimplified. In some clinical trials, certain risks are anticipated, but when the benefits are likely to exceed the risks, the trial can proceed with close interim analyses. Since the outcome of clinical trials is always uncertain, and certain risks are anticipated, it is important to include patients' values. In practice, patients and/or the community should be involved throughout the trials in assessing medical goals and developing trials protocols (45). This leads to the second element, patient preferences.
Patient Preferences (Autonomy)
When medical indications are determined, investigators will proceed to the process of clinical trials. Issues in this element are the ethical, legal, and psychological significance of patient preferences, informed consent, patient competence, and refusal to participate. The protection of research subjects and quality control of trials have been articulated in such guidelines as the Declaration of Helsinki of the World Medical Association, the International Ethical Guidelines for Biornedical Research Involving Human Subjects of the Council for International Organizations of Medical Sciences, and the Belmont Report from the United States (6) . Since the introduction of International Conference on Harmonization Good Clinical Practices (ICH GCP), the issue of patients' preferences has been solved, at least theoretically (7) . However, the claim that "informed consent was obtained" does not necessarily mean that the patient understood the information disclosed by the doctor (8), a common criticism of informed consent practice in developing countries (9) . Also, it should be acknowledged that the competence and judgment of the patient might wax and wane. In the context of the autonomy principle, special attention should be paid to vulnerable people and to other groups of subjects who are free in theory but oppressed by cultural circumstances.
In practice, there is always the possibility of a breach of the principles of informed consent because medicine and doctors are, by nature, paternalistic. Investigators tend to withhold what they consider to be bad news from patients or research subjects. Although such practices are an outgrowth of their good intentions, failure to disclose information is a violation of the principle of informed consent. Some countries endorse the informed consent rule, although it is not influential in modifying the clinical practice of doctors (10,ll) . Experience in these countries suggests that informed consent cannot be implemented by guideline alone, and legislation seems necessary. Involvement of patients in assessment of medical goals is important to attain satisfaction in the trial's outcome (1 2).
The issue of placebo relates to patient preferences. Some people misunderstand and criticize the use of placebo in clinical trials because they cannot differentiate between placebo usage in trials and in clinical medicine. In clinical trials, research subjects are told that they may receive either a test substance or a placebo. They understand that there is no evidence as to which is better; there is no deception involved. This practice is ethical, although the practice of giving unknown test substances to patients may violate the morality of some doctors.
On the other hand, the implication of placebo is different in clinical medicine. The patient is deceived, believing that he or she was given an active drug. Such practices are sometimes ethically acceptable when there are obvious reasons for the use of placebo. However, in most cases, such as giving pa-tients with cancer a less effective pain drug to attain a placebo effect, placebo deception raises genuine moral and ethical questions, and should never be allowed.
A problem may arise in clinical trials when subjects expect the test substance to work better than placebo. Indeed, subjects' decision to participate in clinical trials may be influenced by their "expectations" (13) . However, the test substance may have adverse effects, and patients' and/or doctors' expectations do not necessarily mean that the drug will work. For example, it is well known that antibiotics often resulted in worse outcomes than placebo in salmonellosis and other infectious diseases (14) . The history of drug development and treatment modalities has shown countless failures with drugs and therapeutic interventions despite great expectations. Therefore, there is no doubt that a test substance must be examined in a trial, even if researchers predict that it will be highly effective.
The use of placebo in trials with great expectations does not necessarily imply deception or breach of faith vis-8-vis the patients, as long as that information is disclosed to them. Yet, the question may still be raised, depending on the degree of "expectation." In practice, this is a gray zone from the view of morality, that is, a clinical trial may be ethically acceptable but morally wrong when the "expectation" is great enough to predict the superiority of the test substance over the placebo. In the view of both investigators and patients, full disclosure of information is ethically necessary and close interim analyses are morally required in trials using substances with great expectations. Since there is a gray zone involved, the decision to continue such trials is so difficult that one group may continue but another may stop the trial based on interim analyses (1 5).
Quality of Life
The principal goal of medical intervention is to improve the patient's quality of life (QOL). Issues may include definition and evaluation of QOL, the agent and method to evaluate QOL, factors influencing QOL, and implications regarding sanctity of life. For clinical trials, issues may include the appropriateness of endpoints, and assessment and interpretation of results. These additional issues are important because interpretation of these assessments is subjective, and hence, open to bias.
In some trials, a surrogate endpoint is necessary for purely technical reasons. In other trials, investigators try to camoflauge a surrogate endpoint as a true endpoint. Moreover, clinical doctors often misunderstand a surrogate endpoint as a true endpoint (16) . Therefore, it is an ethical duty for investigators to objectively present their data regarding what is learned and what is left unknown by the trial.
One such concern is an extensive use of relative efficacy rate or relative risk reduction to describe the extent of efficacy. Relative risk reduction is a useful index when studying a disease with a high event rate. Investigators may prefer relative risk reduction because the results are numerically larger (and seem more impressive) than those for absolute risk reduction. To avoid bias and misunderstanding by patients and doctors, absolute risk reduction or number needed to treat (ie, l/ARR) should be presented along with relative efficacy rates for decision making.
Other issues in assessment of results include the discrepancy between meta-analysis and megatrials (17) , and the validity of stratified analysis of trials (1 8). Meta-analysis has been widely adopted to overcome the problem of trial sample size. However, the results of meta-analysis are influenced by several factors, including publication and language biases, which may lead to false positive or negative results. The issue of stratification is important too. Overuse of subgroup analysis leads to improper emphasis on the results of subgroup analysis (1 8) . Subgroup findings should be exploratory, and should rarely affect the trial's conclusions (18) .
Contextual Features
This element deals with broader social concerns surrounding clinical trials, including the family and the third parties concerned; public notions including allegiance and advocacy, confidentiality, cost, or public interest; policy, law, custom, and religion; and local and institutional circumstances where the trial is conducted. Professional ethics are inf luenced by third parties that are involved in clinical trials when their claims are ethically justified. A typical example is the recent dispute over clinical trials on prevention of tuberculosis and perinatal transmission of HIV in developing countries (6, 19, 20, 21) . Issues of for-profit multinational research subject recruiting activity, utility of resources (22) , conflicts of interest between investigators and companies (23) , and the role of the media (24) are also relevant here.
Conducting clinical trials in developing countries raises different issues than conducting the same trials in developed countries. Poverty, infectious diseases, poor nutrition, and inadequate health care systems affect not only the ease of performing trials but also medical indications (6) . The issues of reproductive health and rights are totally different in developed and developing countries. Medical resources alone cannot solve these problems (25) . Countries with different cultures and traditions cannot adopt complicated care systems for medical interventions ( 6 2 1).
Furthermore, susceptibility to test substances may depend on ethnicity. Therefore, questions already solved in one (developed) country sometimes need to be raised again in another (developing) country. This practice has been misunderstood by the general public and by researchers, as if the trial were undermining the human rights of research subjects. On the other hand, conducting clinical trials in developing countries to test drugs for use solely in developed countries violates the deepest principles of ethics (6) .
The cost of medical care continues to rise in all countries. Even developed countries are struggling to constrain health care costs, although the problems of resource allocation may be greater among developing countries. Thus, cost-benefit analysis becomes a crucial issue in developing and developed countries (22) . Treatment strategies must be formulated in the context of the health care system of each country, although a "double standard'' should be avoided.
ETHICAL ANALYSIS OF CLINICAL TRIALS
Although some elements of ethical analysis overlap, the problems and issues of trials can be illustrated by this analysis. Each element is illustrated by an example of clinical trials and drug development policies.
Issues Related to Medical Indications
Solivudine is a potent herpes virus DNA metabolism inhibitor of a deoxyuridine-derivative. On September 3, 1993, it was released to clinicians with the catchphrase "a more potent and safer drug for herpes-zoster." On September 19, one patient died of bone marrow suppression. Then seven patients who had been given solivudine and anti-cancer fluorouracils became seriously ill; three died. The Japanese Ministry of Health and Welfare circulated the Pharmaceuticals and Medical Devices Safety Information on October 12, but it could not prevent the deaths of patients with herpes-zoster who were taking solivudine. By November 25, when solivudine was withdrawn from the market, 23 patients were seriously ill; 15 of these patients died.
Astonishing facts were later disclosed to the media (26). Three of the 244 patients enrolled in the trial had died of the same cause during the trial. These patients were enrolled at university hospitals, but investigators considered these incidences to be irrelevant to the drug's safety. Furthermore, the company already had pretrial toxicology results that showed the fatal adverse effects of solivudine on experimental animals. These animal experiments showed that the toxic effect was heightened when solivudine was given simultaneously with fluorouracils. These fatal results in animal toxicology experiments were hidden, and only the result of leucopenia was reported to the chief investigator and the Japanese Ministry of Health and Welfare. The instructions for doctors warned them to use solivudine very carefully for patients who were being treated for other diseases. However, past experience repeatedly showed that the instructions for doctors and the Japanese Ministry of Health and Welfare's Pharmaceuticals and Medical Devices Safety Information would not change the prescribing behavior of Japanese doctors. That was exactly what happened in this case.
In epilog, the drug company's staff sold their shares in the stock market just before the media exposed this case. Attending doctors and the drug company each accused the other of being responsible for this tragedy.
Issues Regarding Patients' Preferences
Since the introduction of ICH GCP, there should be no question about patient preferences, because strict adherence to the informed consent rule is necessary for clinical trials in all countries. However, this is still a problem in trials involving cancer patients in Japan, since many cancer patients are not told the truth. Some hospitals endorse a strict informed consent rule, but others loosen the rule and exclude cancer patients. They continue to obtain consent from the family, isolating the patient from decision making. The Japanese Ministry of Health and Welfare appears to accept this breach of the rule as part of a "Japanese form" of informed consent, based on paternalism and a different interpretation than Western society (27) .
Although concealing the truth from cancer patients was once widespread, there is no clinical rationale for this practice (28) . Even in Japan, truth is disclosed without causing unpredictable problems in cancer patients (28) . This is often attributed to cultural and ethical issues. However, cross-cultural differences in disclosing the truth refers to the degree of understanding, whereas "culture" simply means the historically maintained current practice (29) . Thus, exclusion of can-cer patients from the informed consent rule is in no way rational.
Issues Regarding Quality of Life
Drug policy depends upon assessment and interpretation of data obtained from clinical trials and studies. The problems are exemplified by the issue of nonsteroidal anti-inflammatory drugs (NSAIDs) and Japanese influenza encephalitis/encephalopathy. It is well known that a peculiar type of influenza encephalitis/encephalopathy is prevalent exclusively among infants in Japan (30, 31) . This is not a recent phenomenon; the Japanese Ministry of Health and Welfare has set up several study groups to investigate this disorder. One of the ministry's aims is to elucidate the link between encephalopathy and NSAIDs, considering the relationship between Reye's syndrome and aspirin. One study group found that encephalopathic infants who had been given NSAIDs had a significantly higher fatality rate than those who had not received NSAIDs (32) . The latest study group found adjusted risks of fatality among clinical encephalopathic infants (odds ratio, 95% confidence interval) of 4.60 (1.03 to 20.49) and 3 .05 (1.01 to 9.21) for mefenamic acid and diclofenac sodium, respectively (33) . The result was confirmed with respect to diclofenac sodium in the following year (34) . The Japanese Ministry of Health and Welfare drew the conclusion that the role of NSAIDs in encephalitis/encephalopathy was not clear yet (34) .
Ironically, the high prevalence of encephalitis/encephalopathy (despite the absence of aspirin usage in acute febrile viral illness in Japan) is employed as evidence against the aspirin theory of Reye's syndrome (31) . However, doctors in Japan routinely prescribe NSAIDs such as mefenamic acid, diclofenac sodium, and others for infant acute viral febrile illness. Often, infants are given a combination of antipyretics and one or two NSAIDs, as shown in the results of the Japanese Ministry of Health and Welfare study groups (32, 33) . If aspirin is related to Reye's syndrome, the Japanese situation is likely to become even more serious than those countries where only aspirin was used for febrile children. These findings seem sufficient to recommend banning NSAIDs for use in infant acute viral febrile illness, at least until NSAIDs are found to be innocent in encephalopathy. Yet, no such policy conclusions have been adopted; the Japanese Ministry of Health and Welfare has only advised doctors not to use diclofenac sodium for established influenza encephalitis/encephalopathy (34) .
Issues Regarding Contextual Features
These ethical issues include the rationale for conducting additional trials after positive results from another country are available, justification to include placebo groups, acceptance of the "local standard of care," the quality of informed consent, and other sitespecific issues regarding medical intervention. Although these have been discussed extensively before (6, 19, 20, 21) , the value of "equivalence studies" and the use of placebo deserve further clarification.
Perinatal transmission of HIV occurs at a rate of 15% to 25% in developed countries (with bottle feeding) and at a rate of 20% to 30% in developing countries (with breast feeding) (35) . Although zidovudine did not always prevent vertical transmission of HIV (36) , some studies showed that vertical transmission was not observed in 11 cases where the mother had been given zidovudine during pregnancy (37, 38) . These highly promising data, though preliminary, were available when the protocol for the PACTG 076 study was developed (39) . Researchers expected zidovudine to prevent vertical transmission of HIV. The study showed that about 17% of subjects benefited but 8% did not benefit from this very sophisticated method.
If the PACTG 076 regimens had been introduced to the Thai trial (40) as an "active control arm," the expected absolute reduction rate would have been 17%, a figure not very different from the corresponding figure (15% to 25% minus 0/11%) at the time the protocol for the PACTG 076 was developed. If the first Thai study had been unethical, the PACTG 076 study would have been also unethical. Thus, the use of placebo was an issue of medical indications rather than a contextual feature.
On the other hand, the issue of "equivalence studies" belongs to this contextual feature. The question is: for whom was the equivalence study intended? There were three possible outcomes in the equivalency study between the PACTG 076 and the oral short course zidovudine (OSCZ) regimens for prevention of perinatal transmission of HIV 1. The PACTG 076 regimen was superior to 2. The PACTG 076 regimen was inferior to 3. The two regimens resulted in equivalent the OSCZ regimen, the OSCZ regimen, or outcomes.
In any of these three possible outcomes, the sophisticated procedure of the PACTG 076 regimen would have never been implemented in developing countries, whereas the OSCZ regimen could have been introduced to developed countries if this regimen had been equal or superior to the PACTG 076 regimen. Thus, obviously the equivalence study was meant for developed countries. If the equivalence study between the PACTG 076 and the OSCZ regimens had been necessary, it should have been performed in developed countries where both regimens were possible. It is true that about 20 (10%) research subjects would have benefited from such an equivalence study in the Thai trial. Therefore, the equivalence study was not wrong in a moral sense. However, the inclusion of the effective regimen solely for comparison within the clinical trial, with no intention to implement the effective regimen after the trial, would be ethically questionable.
Shorter course and/or smaller dosage regimens may sometimes be superior to lengthy authentic regimens (41) . These regimens were tested primarily to benefit people in developing countries where target diseases were prevalent. Eventually, these less burdensome regimens were found to be beneficial to people in developed countries as well.
Thus, the crucial question of the contextual feature is: who benefits from clinical trials? This issue was raised recently in a trial of hepatitis E virus vaccine in Nepal (42). This trial was intended to benefit people in developed and developing countries. However, people in developing countries will benefit more by sanitation and the development of health care infrastructures than by vaccines (42). Furthermore, based upon the global economic system (including health care resources), it is likely that people and pharmaceutical companies in developed countries will benefit more than people in developing countries where vaccine trials are conducted will benefit. Assurance of continuous benefits is needed for the people in the country where such clinical trials are conducted.
IS ETHICAL ANALYSIS NECESSARY FOR CLINICAL TRIALS?
Whether a particular substance is called a drug or a toxin depends on humans' reaction to it. Clinical trials are conducted because there is ample prior evidence or an expectation that the test substance will be beneficial to humans. Unfortunately, this is not true in all cases, so this mode of action must be studied in trials before general implementation in clinical practice. Therefore, clinical trials are a kind of second choice by their very nature, involving uncertainty from the very beginning. Inherent characteristics of clinical trials necessitate that ethics be considered for those concerned. Problems in clinical trials have been presented with respect to the elements most relevant to ethical analysis. Medical indications are important in decisions to start clinical trials, but they are too often neglected. The solivudine case illustrates what happens if investigators close their eyes to unfavorable events and pharmaceutical companies hide their data. Investigators' conclusions may be distorted from the data, as described in the NSAIDs/encephalopathy studies in Japan.
To assure the effect of the ICH GCP, full disclosure of information is essential in clinical trials.
When conducting clinical trials in developing countries, the benefits of the trials should be shared by the people who contributed to them, not only by the people who ordered them. Unfortunately, there are conflicts of interest between research subjects, investigators, and pharmaceutical companies. Pharmaceutical companies in developed countries that sponsor most clinical trials will not benefit immediately from improvements in the health care infrastructure in developing countries. The situation may be getting worse for research subjects and patients in developing countries, due to increasing competition and pressure from globalization, in which pharmaceutical companies are heavily involved. The principle of sharing benefits with subjects should always be remembered in clinical trials.
Ethical considerations imply that there will be moral arguments. Moral arguments are necessary to provide society with tension and to keep advancing toward a healthier society. However, it is essential that the discussion be based on full understanding of medical science and other ethical considerations in clinical trials. At the same time, when morals and ethics are different, there is always a hazard that investigators and pharmaceutical companies will use ethics as an excuse to avoid their moral duties to research subjects. Ethics should not be used as a waiver from moral duties.
ARE THERE ASIA-SPECIFIC ETHICS FOR CLINICAL TRIALS?
The problems in clinical trials described here are primarily derived from incidents that occurred in Japan. Many erroneous Japanese Ministry of Health and Welfare decisions resulted in countless victims of chloroquine retinopathy, thalidomide embryopathy, and HIV infection through blood products (26). This misconduct was primarily due to insufficient analysis of medical indications, ignoring patient preferences, and assessment of the results of clinical trials by investigators. These problems were caused by sabotage by persons who should have been responsible for acting properly. Therefore, these problems were not derived from Asia-specific values. Indeed, most issues in ethical considerations of clinical trials are subjects of universal concern, as discussed extensively concerning the recent Gelsinger case at the University of Pennsylvania in the United States (43) . It has been said that the difference in morality is particularly marked between Eastern and Western values. Certainly, there is Asiaspecific morality, which constitutes a contextual feature of ethical analysis. Such Asia-specific morality is more important in clinical medicine than in clinical trials. On the other hand, there are social issues relating to Asiaspecific contextual features of clinical trials. These subjects are inherent not only in Asia; every society has its own specific needs.
If there are any Asia-specific ethics, it is the issue of who benefits from clinical trials. Globalization tends to ignore individual society needs, especially those of developing countries. When clinical trials are planned in Asia, it is the ethical duty of investigators and pharmaceutical companies to consider the specific needs and benefits of Asian people.
In conclusion, the ethical analysis described here is really synonymous with the basic principles of the Declururion of Helsinki regarding clinical research involving humans (44) . The ethical analysis described here is also summarized in the three principles articulated in the Belmont Report: respect for persons (the recognition of the right of persons to exercise autonomy), beneficence (the minimization of risk incurred by research subjects and the maximization of benefits to them and to others), and justice (the principle that therapeutic investigations should not unduly involve persons from groups unlikely to benefit from subsequent applications of the research) (6) .
